Abstract

Summary: This study aimed to explore the effect of bisphosphonate treatment on stroke using a large population cohort study. We found that the patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (hazard ratio (HR)00.79; 95% confidence interval (CI)00.66-0.99; p00.005) during a 2-year follow-up period. Introduction: Animal models have suggested that bisphosphonates have a beneficial effect on the cardiovascular system. However, data on this topic in human subjects are still lacking. This study aimed to explore the protective effect of bisphosphonate treatment on stroke using a large population cohort study. Methods: We identified 2,148 patients who received bisphosphonate therapy for osteoporotic fractures. We randomly extracted 6,444 subjects with vertebral or hip fractures as a comparison group matched with the study group on age, sex, and year of index date. Each patient was individually tracked for 2 years to identify those who suffered a stroke. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of stroke. Results: We found that 184 (8.6%) patients who received bisphosphonate therapy and 696 (10.8%) comparison patients suffered a stroke during the follow-up period. After adjusting for demographic variables and medical comorbidities, stratified Cox proportional hazards regressions stratified by propensity score revealed that patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (HR00.79; 95% CI0 0.66-0.99). The adjusted HR for subarachnoid/intracerebral hemorrhage for patients who received bisphosphonate therapy was only 0.53 times (95% CI00.33-0.92) that of comparison patients, and the hazard of having an ischemic stroke during the 2-year follow-up period was 0.81 times that of comparison patients (95% CI00.65-0.96). Conclusion: Patients who received bisphosphonate therapy were associated with a lower risk of stroke during a 2-year follow-up period.

Original languageEnglish
Pages (from-to)2551-2557
Number of pages7
JournalOsteoporosis International
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Diphosphonates
Stroke
Population
Therapeutics
Cohort Studies
Propensity Score
Osteoporotic Fractures
Cerebral Hemorrhage
Hip Fractures
Subarachnoid Hemorrhage
Cardiovascular System
Comorbidity
Research Design
Animal Models
Age Groups
Demography
Confidence Intervals

Keywords

  • Atherosclerosis
  • Bisphosphonate
  • Osteoporosis
  • Stroke

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. / Kang, J. H.; Keller, J. J.; Lin, H. C.

In: Osteoporosis International, Vol. 23, No. 10, 10.2012, p. 2551-2557.

Research output: Contribution to journalArticle

@article{9989c06906f34bef95bb10282ee1ac69,
title = "A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke",
abstract = "Summary: This study aimed to explore the effect of bisphosphonate treatment on stroke using a large population cohort study. We found that the patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (hazard ratio (HR)00.79; 95{\%} confidence interval (CI)00.66-0.99; p00.005) during a 2-year follow-up period. Introduction: Animal models have suggested that bisphosphonates have a beneficial effect on the cardiovascular system. However, data on this topic in human subjects are still lacking. This study aimed to explore the protective effect of bisphosphonate treatment on stroke using a large population cohort study. Methods: We identified 2,148 patients who received bisphosphonate therapy for osteoporotic fractures. We randomly extracted 6,444 subjects with vertebral or hip fractures as a comparison group matched with the study group on age, sex, and year of index date. Each patient was individually tracked for 2 years to identify those who suffered a stroke. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of stroke. Results: We found that 184 (8.6{\%}) patients who received bisphosphonate therapy and 696 (10.8{\%}) comparison patients suffered a stroke during the follow-up period. After adjusting for demographic variables and medical comorbidities, stratified Cox proportional hazards regressions stratified by propensity score revealed that patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (HR00.79; 95{\%} CI0 0.66-0.99). The adjusted HR for subarachnoid/intracerebral hemorrhage for patients who received bisphosphonate therapy was only 0.53 times (95{\%} CI00.33-0.92) that of comparison patients, and the hazard of having an ischemic stroke during the 2-year follow-up period was 0.81 times that of comparison patients (95{\%} CI00.65-0.96). Conclusion: Patients who received bisphosphonate therapy were associated with a lower risk of stroke during a 2-year follow-up period.",
keywords = "Atherosclerosis, Bisphosphonate, Osteoporosis, Stroke",
author = "Kang, {J. H.} and Keller, {J. J.} and Lin, {H. C.}",
year = "2012",
month = "10",
doi = "10.1007/s00198-012-1894-0",
language = "English",
volume = "23",
pages = "2551--2557",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "10",

}

TY - JOUR

T1 - A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke

AU - Kang, J. H.

AU - Keller, J. J.

AU - Lin, H. C.

PY - 2012/10

Y1 - 2012/10

N2 - Summary: This study aimed to explore the effect of bisphosphonate treatment on stroke using a large population cohort study. We found that the patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (hazard ratio (HR)00.79; 95% confidence interval (CI)00.66-0.99; p00.005) during a 2-year follow-up period. Introduction: Animal models have suggested that bisphosphonates have a beneficial effect on the cardiovascular system. However, data on this topic in human subjects are still lacking. This study aimed to explore the protective effect of bisphosphonate treatment on stroke using a large population cohort study. Methods: We identified 2,148 patients who received bisphosphonate therapy for osteoporotic fractures. We randomly extracted 6,444 subjects with vertebral or hip fractures as a comparison group matched with the study group on age, sex, and year of index date. Each patient was individually tracked for 2 years to identify those who suffered a stroke. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of stroke. Results: We found that 184 (8.6%) patients who received bisphosphonate therapy and 696 (10.8%) comparison patients suffered a stroke during the follow-up period. After adjusting for demographic variables and medical comorbidities, stratified Cox proportional hazards regressions stratified by propensity score revealed that patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (HR00.79; 95% CI0 0.66-0.99). The adjusted HR for subarachnoid/intracerebral hemorrhage for patients who received bisphosphonate therapy was only 0.53 times (95% CI00.33-0.92) that of comparison patients, and the hazard of having an ischemic stroke during the 2-year follow-up period was 0.81 times that of comparison patients (95% CI00.65-0.96). Conclusion: Patients who received bisphosphonate therapy were associated with a lower risk of stroke during a 2-year follow-up period.

AB - Summary: This study aimed to explore the effect of bisphosphonate treatment on stroke using a large population cohort study. We found that the patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (hazard ratio (HR)00.79; 95% confidence interval (CI)00.66-0.99; p00.005) during a 2-year follow-up period. Introduction: Animal models have suggested that bisphosphonates have a beneficial effect on the cardiovascular system. However, data on this topic in human subjects are still lacking. This study aimed to explore the protective effect of bisphosphonate treatment on stroke using a large population cohort study. Methods: We identified 2,148 patients who received bisphosphonate therapy for osteoporotic fractures. We randomly extracted 6,444 subjects with vertebral or hip fractures as a comparison group matched with the study group on age, sex, and year of index date. Each patient was individually tracked for 2 years to identify those who suffered a stroke. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of stroke. Results: We found that 184 (8.6%) patients who received bisphosphonate therapy and 696 (10.8%) comparison patients suffered a stroke during the follow-up period. After adjusting for demographic variables and medical comorbidities, stratified Cox proportional hazards regressions stratified by propensity score revealed that patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (HR00.79; 95% CI0 0.66-0.99). The adjusted HR for subarachnoid/intracerebral hemorrhage for patients who received bisphosphonate therapy was only 0.53 times (95% CI00.33-0.92) that of comparison patients, and the hazard of having an ischemic stroke during the 2-year follow-up period was 0.81 times that of comparison patients (95% CI00.65-0.96). Conclusion: Patients who received bisphosphonate therapy were associated with a lower risk of stroke during a 2-year follow-up period.

KW - Atherosclerosis

KW - Bisphosphonate

KW - Osteoporosis

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84864815723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864815723&partnerID=8YFLogxK

U2 - 10.1007/s00198-012-1894-0

DO - 10.1007/s00198-012-1894-0

M3 - Article

C2 - 22270858

AN - SCOPUS:84864815723

VL - 23

SP - 2551

EP - 2557

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 10

ER -